A rare autoimmune disorder was behind Mr Hazwady Nazran's paranoid delusions, memory loss and seizures. Read more at ...

Researchers have developed a cellular fractionation protocol. This method allows for precise analysis of the proteins located ...

Like a lock and key, ketamine binds to the brain via N-methyl-D-aspartate (NMDA) receptors. NMDA receptors are all over the brain and are essential in maintaining consciousness. The study came ...

Apimostinel has a similar mode of action to ketamine and derivatives like Johnson & Johnson's Spravato (esketamine) – ...

Relmada halted Phase 3 trials of NMDA receptor blocker for depression but will continue its early psilocybin program while ...

Relmada Therapeutics will halt two Phase III trials of a major depressive disorder drug after a futility assessment and ...

It is the first and only oral NMDA receptor antagonist to be approved for this use, and the first oral therapy with a new mechanism of action in around 60 years, said Axsome. NMDA antagonist ...

Following the news, shares of Relmada had plunged sharply. REL-1017 is a new chemical entity or NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels ...

AV-101 is a small molecule commercialized by VistaGen Therapeutics, with a leading Phase I program in Drug-Induced Dyskinesia.

In this study, recently published in Alzheimer's & Dementia, the authors investigated NMDA (N-methyl-D-aspartate receptors) receptors due to their importance in synaptic transmission and their ...